Skip to Content

Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in Breast Cancer Patients Previously Treated with Endocrine Therapy

A new study presented at the 2024 ASCO Annual Meeting shows that trastuzumab deruxtecan outperforms standard chemotherapy in delaying cancer progression for HR+, HER2-low, and HER2-ultralow metastatic breast cancer patients.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top